Clinical Rheumatology

, Volume 37, Issue 11, pp 3025–3032 | Cite as

Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis

  • Arwa Mohammad Hassan
  • Nessma Mohamed Ahmed Farghal
  • Doaa Salah HegabEmail author
  • Wesam Salah Mohamed
  • Hend Hassan Abd-Elnabi
Original Article


Juvenile systemic lupus erythematosus (jSLE) is a multisystem autoimmune disease of unpredicted course and prognosis. Rates of organ involvement in SLE are higher in children, and overt lupus nephropathy is more often a presenting manifestation of SLE in children than adults. Inflammatory soluble chemokine CXC motif-ligand 16 (sCXCL16) is an important pathogenic mediator in inflammatory diseases as SLE. Herein, we aimed to evaluate serum level of sCXCL16 in jSLE patients in comparison to healthy controls and to correlate it with disease activity and extent of cutaneous and renal affection, to detect its possible role in disease pathogenesis. Serum level of sCXCL16 was determined by ELISA in 27 patients with jSLE (mean age 12.35 years ± 2.26 SD) in addition to 30 age- and sex-matched healthy controls and correlated with clinical and laboratory parameters in lupus group. Serum sCXCL16 was significantly higher in jSLE patients than controls (P ≤ 0.001), and it correlated positively with SLE disease activity, severity of lupus nephritis, 24-h urinary protein, anti-dsDNA titre, blood pressure, and ESR, while it correlated negatively with serum C3 levels. Serum sCXCL16 was higher in jSLE patients with alopecia and malar erythema. Serum sCXCL16 might play a role in inflammatory pathogenesis of jSLE particularly in periods of disease activity. It might serve as a future useful laboratory test for detection of jSLE activity, renal insult, and its severity which might limit the need for invasive renal biopsies in such a delicate patient population.


Activity Chemokine Cutaneous lupus Juvenile Lupus nephritis 


Compliance with ethical standards

An informed written consent was obtained from the parents of all the included children before participation, and the study was approved by the institutional review board of the research ethics committee of Quality Assurance Unit, Faculty of Medicine, Tanta University.




  1. 1.
    Cunha JS, Gilek-Seibert K (2016) Systemic lupus erythematosus: a review of the clinical approach to diagnosis and update on current targeted therapies. R I Med J (2013) 99(12):23–27Google Scholar
  2. 2.
    Teruel M, Alarcón-Riquelme ME (2016) The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun 74:161–175CrossRefGoogle Scholar
  3. 3.
    Klein-Gitelman M, Reiff A, Silverman ED (2002) Systemic lupus erythematosus in childhood. Rheum Dis Clin N Am 28(561–77):vi–viiGoogle Scholar
  4. 4.
    Klein-Gitelman MS, Miller ML (1996) Systemic lupus erythematosus. Indian J Pediatr 63(4):485–500CrossRefGoogle Scholar
  5. 5.
    Abdel-Hafez MA, Abdel-Nabi H (2015) Juvenile systemic lupus erythematosus: onset patterns and short-term outcome in Egyptian children, a single-center experience. Lupus 24(13):1455–1461CrossRefGoogle Scholar
  6. 6.
    Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787–820CrossRefGoogle Scholar
  7. 7.
    van Lieshout AW, van der Voort R, Toonen LW, van Helden SF, Figdor CG, van Riel PL, Radstake TR, Adema GJ (2009) Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Ann Rheum Dis 68(6):1036–1043CrossRefGoogle Scholar
  8. 8.
    Petit SJ, Wise EL, Chambers JC, Sehmi J, Chayen NE, Kooner JS, Pease JE (2011) The CXCL16 A181V mutation selectively inhibits monocyte adhesion to CXCR6 but is not associated with human coronary heart disease. Arterioscler Thromb Vasc Biol 31:914–920CrossRefGoogle Scholar
  9. 9.
    Borst O, Schaub M, Walker B, Sauter M, Muenzer P, Gramlich M, Mueller K, Geisler T, Lang F, Klingel K, Kandolf R, Bigalke B, Gawaz M, Zuern CS (2014) CXCL16 is a novel diagnostic marker and predictor of mortality in inflammatory cardiomyopathy and heart failure. Int J Cardiol 176(3):896–903CrossRefGoogle Scholar
  10. 10.
    Qin M, Guo Y, Jiang L, Wang X (2014) Elevated levels of serum sCXCL16 in systemic lupus erythematosus; potential involvement in cutaneous and renal manifestations. ClinRheumatol 33(11):1595–1601Google Scholar
  11. 11.
    Matloubian M, David A, Engel S, Ryan JE, Cyster JG (2000) A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 1:298–304CrossRefGoogle Scholar
  12. 12.
    Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Föller M, Gawaz M, Lang F (2012) Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 302:C644–C651CrossRefGoogle Scholar
  13. 13.
    Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S, Ludwig A (2004) The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172:6362–6372CrossRefGoogle Scholar
  14. 14.
    Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, Greenberg HB, Butcher EC (2001) Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 107:595–601CrossRefGoogle Scholar
  15. 15.
    Van d V, van Lieshout AW, Toonen LW, Sloetjes AW, van den Berg WB, Figdor CG et al (2005) Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 52:1381–1391CrossRefGoogle Scholar
  16. 16.
    Sato T, Thorlacius H, Johnston B, Staton TL, Xiang W, Littman DR, Butcher EC (2005) Role for CXCR6 in recruitment of activated CD8+ lymphocytes to inflamed liver. J Immunol 174:277–283CrossRefGoogle Scholar
  17. 17.
    Gutwein P, Abdel-Bakky MS, Schramme A, Doberstein K, Kampfer-Kolb N, Amann K et al (2009) CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 174:2061–2072CrossRefGoogle Scholar
  18. 18.
    Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Nino MD et al (2012) TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubule-interstitial inflammation. Kidney Int 81:1098–1107CrossRefGoogle Scholar
  19. 19.
    Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Niño MD, Carrero JJ, Ortiz A (2014) CXCL16 in kidney and cardiovascular injury. Cytokine Growth Factor Rev 25(3):317–325CrossRefGoogle Scholar
  20. 20.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefGoogle Scholar
  21. 21.
    Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM, American College of Rheumatology (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64(6):797–808CrossRefGoogle Scholar
  22. 22.
    Churg J, Sobin LH (1982) Lupus nephritis. Renal disease, classification and atlas of glomerular diseases. Igaku-Shoin, New York, pp 127–149Google Scholar
  23. 23.
    Gladman DD, Lbanez D, Urowitz MB (2000) Systemic lupus erythematosus Disease Activity Index 2000. J Rheumatol 29:288–291Google Scholar
  24. 24.
    Pluchinotta FR, Schiavo B, Vittadello F, Martini G, Perilongo G, Zulian F (2007) Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus 16:550–555CrossRefGoogle Scholar
  25. 25.
    Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED (2008) Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. Pediatr 152:550–556CrossRefGoogle Scholar
  26. 26.
    Bakr A (2005) Epidemiology treatment and outcome of childhood systemic lupus erythematosus in Egypt. PediatrNephrol 20:1081–1086Google Scholar
  27. 27.
    Salah S, Lotfy HM, Sabry SM, El Hamshary A, Taher H (2009) Systemic lupus erythematosus in Egyptian children. Rheumatol Int 29:1463–1468CrossRefGoogle Scholar
  28. 28.
    Dung NT, Loan HT, Nielsen S, Zak M, Petersen FK (2012) Juvenile systemic lupus erythematosus onset patterns in Vietnamese children: a descriptive study of 45 children. Pediatr Rheumatol 10:38–43CrossRefGoogle Scholar
  29. 29.
    Manzi S (2001) Epidemiology of systemic lupus erythematosus. Manag Care 7(16 Suppl):S474–S479Google Scholar
  30. 30.
    Pattaragarn A, Sumboonnanonda A, Parichatikanond P, Supavekin S, Suntornpoch V, Vongjirad A (2005) Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients. J Med Assoc Thail 8:232–241Google Scholar
  31. 31.
    Ramirez Gomez LA, Uribe Uribe O, Osio Uribe O, Grisales Romero H, Cardiel MH, Wojdyla D et al (2008) Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 17:596–604CrossRefGoogle Scholar
  32. 32.
    Garcia GE, Truong LD, Zhang P, Johnson RJ, Wilson CB, Feng L et al (2007) Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 170(5):1485–1496CrossRefGoogle Scholar
  33. 33.
    Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C (2007) Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 179(10):7166–7175CrossRefGoogle Scholar
  34. 34.
    Wen S, He F, Zhu X, Yuan S, Liu H, Sun L (2018) IFN-γ, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus. Clin Exp Rheumatol 36(1):36–43PubMedGoogle Scholar
  35. 35.
    Gedalia A, Molina JF, Molina J, Uribe O, Malagon C, Espinoza LR (1999) Childhood-onset systemic lupus erythematosus: a comparative study of African-Americans and Latin Americans. Natl Med Assoc 91:497–501Google Scholar
  36. 36.
    Kole AK, Ghosh A (2009) Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center. Indian J Dermatol 54(2):132–136CrossRefGoogle Scholar
  37. 37.
    Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074–2823CrossRefGoogle Scholar
  38. 38.
    Xia Y, Entman ML, Wang Y (2013) Critical role of CXCL16 in hypertensive kidney injury and fibrosis. Hypertension 62:1129–1137CrossRefGoogle Scholar
  39. 39.
    Ting CK, Hsieh KH (1992) A long-term immunological study of childhood onset systemic lupus erythematosus. Ann Rheum Dis 51(1):45–51CrossRefGoogle Scholar
  40. 40.
    Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD (1991) Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 18(6):678–685CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Dermatology and Venereology Department, Faculty of MedicineTanta UniversityTantaEgypt
  2. 2.Clinical Pathology Department, Faculty of MedicineTanta UniversityTantaEgypt
  3. 3.Pediatrics Department, Faculty of MedicineTanta UniversityTantaEgypt

Personalised recommendations